Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Author: Stein, A.
Martinelli, G.
Hughes, T.
Muller, M.
Beppu, L.
Gottardi, E.
Branford, S.
Soverini, S.
Woodman, R.
Hochhaus, A.
Kim, D.
Saglio, G.
Radich, J.
Citation: BMC Cancer, 2013; 13(1):1-10
Publisher: BioMed Central Ltd.
Issue Date: 2013
ISSN: 1471-2407
Statement of
Andrew M Stein, Giovanni Martinelli, Timothy P Hughes, Martin C Müller, Lan Beppu, Enrico Gottardi, Susan Branford, Simona Soverini, Richard C Woodman, Andreas Hochhaus, Dong-Wook Kim, Giuseppe Saglio and Jerald P Radich
Abstract: BACKGROUND We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses. METHODS Patients from the nilotinib registration trial (CAMN107A2101; registered at webcite as NCT00109707) who had imatinib-resistant or -intolerant Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) or accelerated phase with BCR-ABL1 > 10% (on the international scale [IS]) at baseline and, in the first 6 months, had at least three BCR-ABL1 transcript measurements and an average daily dose of at least 720 mg were included in this analysis (N = 123). RESULTS More than half of patients (65/123; 53%) had a slow monophasic response and the remainder (58/123; 47%) had a biphasic response, in which patients had a rapid initial decrease in BCR-ABL1 transcripts followed by a more gradual response. The biphasic response type strongly correlated with improved event-free survival (EFS). Data in the first 6 months of follow-up were sufficient to predict EFS at 24 months. CONCLUSIONS Unlike newly diagnosed patients with Ph+ CML-CP—in whom the majority had a biphasic response—approximately half of patients with imatinib-resistant or -intolerant CML had a slower, monophasic response. Second-line patients who did have a biphasic response had an EFS outlook similar to that of newly diagnosed patients treated with imatinib. Our model was comparable to using BCR-ABL1 (IS) ≤ 10% at 6 months as a threshold for predicting EFS.
Keywords: Chronic myeloid leukemia; Nilotinib; Mathematical modeling; BCR-ABL; Molecular response
Rights: © 2013 Stein et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
RMID: 0020138081
DOI: 10.1186/1471-2407-13-173
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_83386.pdfPublished version552.08 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.